Could a single infusion of engineered immune cells tame stubborn autoimmune diseases?

NCT ID NCT07059169

Recruiting now Disease control Sponsor: LiangZou Source: ClinicalTrials.gov ↗

First seen Apr 25, 2026 · Last updated Apr 29, 2026 · Updated 1 time

Summary

This early study is testing a new treatment called CD19 CAR-T for people with severe autoimmune diseases like lupus, Sjogren's syndrome, and scleroderma that haven't improved with standard therapies. The treatment involves taking a patient's own immune cells, modifying them in a lab to target and destroy faulty immune cells, and infusing them back. The main goals are to check safety and find the right dose, with 20 participants being closely monitored for side effects and initial signs of disease control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Wuhan No.1 Hospital
RECRUITING

Wuhan, Hubei, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

AUTOIMMUNE DISEASES